the Web site devoted to the study of the glucagon-like peptides
This Web site is maintained by Dr. Daniel J. Drucker, Mount Sinai Hospital Samuel Lunenfeld Research Institute Banting and Best Diabetes Centre, University of Toronto
Exenatide + Rosiglitazone + metformin See Exendin-4: Human Data
Liraglutide (Victoza) receives FDA approval January 25 2010 See Liraglutide for US prescribing and safety information
DPP-4 inhibition and outcomes after experimental LAD ligation in mice See DPP-4 and the Cardiovascular System
GIP receptor variation influences insulin secretion and postprandial glucose in normal human subjects See GIP Receptor
Sitagliptin acute improves myocardial function in human subjects with ischemic heart disease DPP-4 and the Cardiovascular System
GLP-1 actions in the immune system See GLP-1 actions independent of glucose homeostasis
Saxagliptin/TZD combination therapy See Saxagliptin
Sitagliptin and insulin combination therapy See Sitagliptin
